An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
| Status: | Completed |
|---|---|
| Conditions: | Gastroesophageal Reflux Disease |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | November 2007 |
| End Date: | September 2008 |
A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of XP19986 in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)
To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet
compared to placebo in subjects with symptomatic GERD
compared to placebo in subjects with symptomatic GERD
Inclusion Criteria:
- History and documentation of GERD diagnosed by a gastroenterologist, with symptoms
(heartburn and/or regurgitation) on ≥ 3 days during the week prior to screening and
prior to randomization
Exclusion Criteria:
- Current or historical endoscopic evidence of erosive esophagitis LA Classification
Grade B, C, or D
We found this trial at
1
site
Click here to add this to my saved trials
